# Zimmer Biomet Holdings, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Zimmer Biomet Holdings, Inc). ## Overview Zimmer Biomet Holdings is a U.S.-based medical technology company focused on orthopedic reconstruction and related surgical care. Its portfolio includes implants and instruments for knees, hips, extremities, trauma, craniomaxillofacial and thoracic procedures, along with bone cement, surgical products, and digital and robotic technologies used in operating rooms and other care settings. ## Products & services • Knee reconstruction implants and instruments • Hip reconstruction implants and instruments • Extremities, trauma and sports medicine products • Craniomaxillofacial and thoracic products • Bone cement and surgical products • Digital, data and robotic surgery technologies - **Knees** (35%) — Implants, instruments and related systems used in knee reconstruction procedures. - **Hips** (25%) — Hip replacement implants, instruments and associated surgical solutions. - **S.E.T.** (25%) — Sports medicine, extremities, trauma, craniomaxillofacial and thoracic products. - **Technology & Data, Bone Cement and Surgical** (15%) — Robotic, digital and data tools plus bone cement and surgical products. - Knee reconstruction implants and instruments - Hip reconstruction implants and instruments - Extremities, trauma and sports medicine products - Craniomaxillofacial and thoracic products - Bone cement and surgical products - Digital, data and robotic surgery technologies ## Customers Zimmer Biomet sells primarily to orthopedic surgeons, neurosurgeons and other specialists who specify and use its products in surgery. Its products also reach hospitals, hospital systems, ambulatory surgery centers, stocking distributors, healthcare dealers and purchasing organizations that buy for procedure volume, clinical preference and supply reliability. - **Orthopedic surgeons** (primary) — Buy knee, hip, extremity and trauma systems for elective and reconstructive procedures; they value clinical performance and surgeon familiarity. - **Hospitals and hospital systems** (primary) — Purchase implants, instruments and surgical products for inpatient and outpatient procedures, often through direct accounts or consignment. - **Ambulatory surgery centers** (secondary) — Buy orthopedic and sports medicine products for outpatient procedures where speed, availability and standardized kits matter. - **Stocking distributors and healthcare dealers** (secondary) — Buy and resell products in markets where indirect distribution is important and local access matters. - **Specialist surgeons** (secondary) — Includes neurosurgeons and other specialists using CMFT and related products in specialized procedures. - Orthopedic surgeons buying implants and instruments for joint procedures - Neurosurgeons and other specialists using CMFT and related products - Hospitals and hospital systems purchasing for surgical procedure volumes - Ambulatory surgery centers seeking standardized orthopedic solutions - Stocking distributors and healthcare dealers serving local markets - Buying groups and purchasing organizations negotiating access and pricing ## Geography Zimmer Biomet reports sales by the United States and International, with the U.S. representing the core of the Americas segment and roughly 95% of that region's net sales in 2025. The company also operates across Europe, the Middle East and Africa and Asia Pacific, where local distribution systems, regulation and product preferences can shape demand and channel structure. - **United States** (57.8%) — Based on 9M 2025 net sales by geography: US $3,451.4m of $5,987.7m - **International** (42.3%) — Based on 9M 2025 net sales by geography: International $2,536.3m of $5,987.7m - United States is the largest market and anchors the Americas segment - International sales span Europe, Middle East and Africa and Asia Pacific - U.S. represented about 95% of Americas net sales in 2025 - Local regulation and distribution systems affect non-U.S. execution - Currency movements can affect reported international sales ## Strategy Zimmer Biomet's strategy centers on broadening its orthopedic portfolio, pairing implants with digital and robotic technologies, and supporting surgeons through training and medical education. The company also emphasizes channel execution across direct and distributor models, while using product launches and acquisitions to expand its presence in adjacent surgical categories. - **Broaden product and technology portfolio** (medium-term) — A wider portfolio increases procedure coverage and cross-selling across orthopedic and surgical workflows. - **Strengthen surgeon education and commercial execution** (short-term) — These products are technique-sensitive, so adoption depends on training, support and field execution. - **Expand adjacent surgical categories** (medium-term) — Adjacencies reduce dependence on core joint reconstruction and deepen relationships with providers. - **Use acquisitions to add capabilities** (short-term) — Acquisitions can accelerate entry into robotics and other high-value technologies. - Expand the orthopedic portfolio across knees, hips and extremities - Pair implants with digital and robotic surgery technologies - Support surgeon adoption through training and medical education - Use direct and distributor channels to fit local market structures - Add capabilities through acquisitions and product development ## Risks Zimmer Biomet faces intense competition in a market where technology, surgeon preference, pricing and service quality drive share. Its results are also exposed to regulatory approvals, reimbursement pressure, supply chain disruption, foreign exchange, tariffs, cybersecurity and the risk that products become obsolete if innovation slows. - **Intense competitive pressure** [high] — Surgeons and hospitals can switch among device makers based on innovation, quality, pricing and service. - **Healthcare reimbursement and cost containment** [high] — Hospitals and payers may limit procedure volumes, pricing or product adoption to control costs. - **Supply chain disruption** [high] — The company relies on manufacturing, inventory and distribution coordination to support surgical demand. - **Foreign exchange and tariff exposure** [medium] — International sales and cross-border sourcing can be affected by currency swings and trade policy. - **Cybersecurity and IT systems failure** [medium] — Digital tools, customer support and internal operations depend on secure information systems. - **Product obsolescence and innovation risk** [high] — New technologies can displace existing implants or surgical systems if development lags. - Competition is based on technology, quality, service and price - Reimbursement and healthcare cost controls can pressure procedure demand - Supply chain disruptions can cause lost sales and inventory shortages - Foreign exchange and tariffs affect international profitability and pricing - Cybersecurity or IT failures could disrupt operations and customer service - Product obsolescence risk is high in a technology-driven device market ## Accounting Zimmer Biomet's reported results are affected by revenue timing across direct and consignment channels, since a large share of sales is consignment-based and title may remain with the company until use or shipment. Investors should also watch seasonality in elective procedures, intangible asset amortization and impairment risk, and estimates tied to acquisitions, contingent consideration and restructuring-related charges. - **Consignment revenue recognition** — Quarterly revenue volatility and inventory levels - **Seasonality of elective procedures** — Quarter-to-quarter comparability - **Intangible asset amortization and impairment** — Operating income and asset carrying values - **Acquisition and contingent consideration accounting** — Purchase accounting, liabilities and future earnings - **Foreign currency translation** — Reported revenue, expenses and cash balances - Consignment sales affect when revenue is recognized - Elective procedure seasonality can shift quarterly comparisons - Intangible asset amortization rises after acquisitions - Goodwill and intangible impairment risk can affect earnings - Contingent consideration and acquisition accounting require estimates - Foreign currency translation affects international results --- *Last updated: 2026-09-24T12:09:16.064045+00:00*